EX-10.17



 Exhibit 10.17 
 [Execution Copy] 
 TUFTS UNIVERSITY LICENSE AGREEMENT 

This Agreement is made and entered into as of February 1, 1997 (“the Effective Date”), by and between Paratek
Pharmaceuticals, Inc., a Delaware corporation having an address of P.O. Box 1525, Boston, Massachusetts 02117-1525 (“Licensee”) and Tufts University, a/k/a Trustees of Tufts College, a corporation duly organized and existing under the laws
of the Commonwealth of Massachusetts and having a principal office at Medford, Massachusetts 02155 (“Tufts”). 

WHEREAS, Tufts possesses certain know-how, inventions and intellectual property in the field of drug resistance; 

WHEREAS, Tufts, acting through Dr. Stuart Levy, (the “Principal Investigator”) wishes to and is prepared to conduct
additional research in this field under a Sponsored Research Agreement of even date herewith; 
 WHEREAS, Licensee is prepared
to provide support to Tufts for such research by the Principal Investigator, providing it receives certain license rights under inventions, biological materials, and/or know-how developed in the research under
the terms of this License Agreement; and 
 WHEREAS, Tufts wishes to have such inventions, biological materials, and/or know-how perfected and marketed in order that products resulting therefrom might be available for public use and benefit. 
 NOW THEREFORE, for valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, the parties hereto mutually agree as follows: 

ARTICLE I - DEFINITIONS. 
 1.1. “Patent Rights” shall mean rights owned or controlled by Tufts which arise under United States or foreign patents or patent applications as described in Exhibit A or any patents issuing
from said applications that cover inventions which were discovered or developed at Tufts by Dr. Stuart Levy, alone or in conjunction with others, or which are discovered or developed in the Field of Use pursuant to the Sponsored Research
Agreement of even date herewith (the “Research Agreement”), including any divisions, continuations, continuations-in-part,
re-examinations, extensions, renewals, or reissues thereof. 
 1.2.
“Technology” shall mean the trade secret, know-how, and other proprietary, non-public information relating to the “Field of Use” and necessary or useful for practicing the Patent Rights
that was discovered or developed at Tufts by Dr. Stuart Levy, alone or in 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 
conjunction with others, or is discovered or developed pursuant to the Research Agreement and that has been revealed to Licensee pursuant to the Research Agreement or that may hereafter be
revealed to Licensee pursuant to the requirements of this Agreement or the Research Agreement. The Technology shall not include the Patent Rights but shall include any non-public information included in patent
applications if and when it is subsequently deleted therefrom before the patent is issued. 
 1.3. “Confidential
Technology” shall mean all Technology, and all information in or concerning patent applications included in the Patents, provided, however, that Licensee need not keep confidential any information that: 

(a) at the date of its disclosure by Tufts to Licensee was known to Licensee as documented in Licensee’s files and is revealed to
Tufts within thirty (30) days after Tufts’ disclosure to Licensee; or 
 (b) at the date of disclosure by Tufts to
Licensee was, or thereafter becomes, through no fault of Licensee, publicly known through publication or so widely known and used that it can be said to be generally available to the public. 

1.4. “Field of Use” shall mean the prophylaxis, treatment or prevention of bacterial or microbial diseases or medical
conditions in humans or animals or agriculture using (i) tetracycline derivatives or other compounds which affect tetracycline resistance or (ii) compounds based on knowledge of the MAR operon or (iii) compounds involving novel genes
which affect antibiotic resistance or microbial infectivity and which are derived from studies of the MAR operon or (iv) compounds that affect any such genes. 
 1.5. “License Period” shall mean collectively the respective periods commencing on the Effective Date and ending (unless sooner terminated) upon the later of the expiration of the last to expire
of the Patent Rights (treating pending applications as issued patents for so long as they are pending) and fifteen (15) years from the Effective Date. 
 1.6. “Licensed Products” shall mean all products that are within or made by a process within the Field of Use and that embody or are made in accordance with or using or are based upon or derived
from any aspect of the Patent Rights or the Technology. 
 1.7 “Gross Sales” shall mean the gross sales of Licensed
Products subject to royalty under this Agreement billed to customers by Licensee and its Subsidiaries, less the following: 

(a) [***]; 

(b) [***]; and 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 2 








 (c) [***]. 
 Gross Sales shall also include and be deemed to have been made with respect to any Licensed Products used by Licensee or any Subsidiary, for its own commercial purposes, or transferred to any third-party
for less than the transferee is then charging in normal arms-length sales transactions; and Gross Sales in all such cases shall be deemed to have been made at the prices therefor at which such Licensed Products are then being sold to the customers
of such user or transferor (or of Licensee, if a Subsidiary is a user but not a seller) in arms-length sales transactions. 
 In
the event that a Licensed Product under this Agreement is sold in combination with another active ingredient or component having independent therapeutic effect or diagnostic utility, then “Gross Sales,” for purposes of determining royalty
payments on the combination, shall be calculated using one of the following methods: 
  

	 	(e)	By multiplying the Gross Sales of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty paying period in question, of the
Licensed Product sold separately, and B is the gross selling price, during the royalty period in question, of the other active ingredients or components sold separately; or 


 

	 	(f)	In the event that no such separate sales are made of the Licensed Product or any of the active ingredients or components in such combination package during the royalty
paying period in question, Gross Sales, for the purposes of determining royalty payments, shall be calculated using the above formula where A is the reasonably estimated commercial value of the Licensed Product sold separately and B is the
reasonably estimated commercial value of the other active ingredients or components sold separately. Any such estimates shall be made in good faith by Licensee and reported to Tufts with the reports to be provided to Tufts pursuant to
Section 3.7 hereof. 

 1.8. “Subsidiary” shall mean any corporation, partnership, or other business
organization that directly or indirectly controls, is controlled by, or is under common control with Licensee. For the purpose of this Agreement, “control” shall mean the holding directly or indirectly of fifty percent (50%) or more
of the voting stock or other ownership interest of the corporation or other business organization invoiced. 
 1.9.
“Territory” shall mean the world. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 3 








 ARTICLE II - GRANT; SUBLICENSES. 

2.1. Grant. Subject to the terms and conditions hereinafter set forth, Tufts hereby grants to Licensee, to the extent that it
lawfully may, a royalty-bearing, exclusive license to practice the Patent Rights and use the Technology in the Territory, only for the purpose of developing, making, using, and selling Licensed Products (the “License”). The License shall
exist as such an exclusive, royalty-bearing license during and will terminate as such at the end of the License Period, unless sooner terminated as hereinafter provided. If the License does not terminate before the end of the License Period, then
the License to use the Technology shall continue in effect thereafter without limitation of time as an exclusive, fully-paid-up license subject to termination only as provided in Article IX. 

2.2. Reserved Rights. During the License Period, Tufts shall have no right to use the Patent Rights or Technology to make, use, or
sell Licensed Products for commercial purposes, but Tufts reserves to itself (a) the right at all times to practice the Patent Rights and to use the Technology, and to make and use Licensed Products for research purposes within Tufts, and
(b) all other rights not granted to Licensee, including the rights to use and permit the use of Patent Rights and Technology for any purpose not in conflict with the provisions of the License. 

2.3. Sublicenses. Licensee shall also have the right to grant to its Subsidiaries or other sublicensees, exclusive or non-exclusive sublicenses under the License during the License Period; provided, however, and Licensee agrees that: 
 (a) the terms and conditions of each sublicense shall be consistent with the terms and conditions of this Agreement and shall contain, among other things (by way of example but not limitation), provisions
substantially similar to and consistent with: the “Gross Sales” definition; Article III (providing, among other things, that royalties shall be paid to Licensee in amounts at least equal to those of Article III hereof, so that Licensee may
in turn pay those royalties to Tufts); Article V; Section 7.1 (so that no representations or warranties inconsistent with that Article shall be extended to or by any sublicensee); Article IX, but the sublicense must terminate not later than the
end of the License Period, or earlier if the License terminates earlier for any reason; Article XI; and Article XII. 
 (b) each
sublicense shall provide that the obligations to Tufts of Sections 3.8, 3.9, 3.10, 7.1, 8.1, 8.5, and 9.2, and Articles V, XI, and XII of this Agreement shall be binding on the sublicensee and be enforceable both by Tufts and the Licensee.

 (c) if a proposed sublicensee is either (i) a Subsidiary or (ii) a company engaged in the development, manufacture
or distribution of health care products with a net worth or market capitalization of at least $50 million, no approval of Tufts shall be required for the proposed sublicense: in all other cases, the sublicense may not be granted without Tufts’
prior written approval (which may not be unreasonably withheld or delayed); 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 4 








 (d) Licensee shall furnish to Tufts a true and complete copy of each sublicense agreement
and each amendment thereto, promptly after the sublicense or amendment has been agreed upon; 
 (e) no Subsidiary or other
sublicensee shall have the right to further license, sublicense, or assign its rights without the prior approval of Licensee; and 
 (f) no sublicense shall relieve Licensee of any of its obligations hereunder, and Licensee shall be responsible for the acts or omissions of its Subsidiaries and sublicensees and for compliance by them
with their obligations, and Licensee shall take all steps necessary to enforce that compliance to the extent required to allow Licensee to fully comply with all of its obligations under this agreement. 

2.4 During the term of this Agreement and so long as neither Licensee nor any Subsidiary or sublicensee is in default with respect to any
payment due to Tufts hereunder, Tufts will not assert its rights under any Patent Rights to prevent any party from using or selling any quantity of Licensed Product on which a royalty has been paid hereunder. 

ARTICLE III - PAYMENTS; RECORDS. 
 3.1. License Fee. As partial consideration for the licenses granted hereunder, Licensee agrees to issue to Tufts and its designees, within thirty (30) days of the Effective Date, 500,000
shares of Licensee’s Common Stock, par value $0.001 per share, pursuant to the terms of a Stock Subscription and Right of First Refusal Agreement. 
 3.2. Milestone Payments. Licensee agrees to pay to Tufts the following nonrefundable milestone payments: 
  

					
	 Milestone
	  	Payment Amount	 
		
	 Commencement of First Phase III
	  	 	50,000	  
	 Clinical Trials in The United States
	  			
		
	 [***]
	  	 	[***	] 
		
	 [***]
	  	 	[***	] 

 3.3 Minimum Royalties. Licensee agrees to pay to Tufts a minimum royalty payment of Twenty-Five
Thousand Dollars ($25,000) in each twelve-month period commencing on each anniversary of the Effective Date if during such period Licensee is not sponsoring at least One Hundred Thousand Dollars ($100,000) in research at Tufts. Minimum royalty
payments shall be creditable against royalties due under Section 3.4 during the same twelve-month period. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 5 








 3.4. Running Royalties. Licensee agrees to pay to Tufts royalties of: 

(a) [***] percent ([***]%) of the Gross Sales of Licensed Products, the making, using, or selling of which infringes (were it not for the
License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights; or 
 (b) [***]percent ([***]%) of the Gross Sales of Licensed Products that do not fall within the clause (a), above, but the manufacture, use or sale of which would infringe (were it not for the License) at
least one claim in a pending application included in the Patent Rights, if such claim were to issue. 
 3.5 Sublicense
Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts (a) [***] percent ([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to
sublicenses of rights granted to Licensee hereunder, and (b) the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by
a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty
which would be due if Licensee, rather than the sublicensee, had sold the Licensed Product. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for
equity investments in Licensee will not be subject to any royalties hereunder. 
 3.6 Royalty Reductions. In the event
Licensee or a sublicensee of Licensee incurs expenses in judicial or administrative proceedings based upon allegations of infringement by Licensee or sublicensee of third-party patents or know-how solely or
primarily as a result of the sale of Licensed Products, Licensee may withhold up to [***] percent ([***]%) of the royalties due hereunder for the calendar year in which the expenses are incurred, and apply the same toward reimbursement of its
expenses in connection therewith. 
 3.7. Statements; Payments. After the first commercial sale of a Licensed Product,
Licensee shall, within sixty (60) days after the last days of March, June, September, and December in each year or portion thereof during the License Period, and within sixty (60) days after the end of the License Period, provide Tufts
with a statement accounting for the Gross Sales of Licensed Products by Licensee, its Subsidiaries, and its sublicensees and all amounts described in Section 3.5, all for the immediately preceding three (3) month period or portion thereof,
accompanied by payment for the full amount of royalties due under this Article III for that period or portion thereof. Each such statement shall be certified by the Chief Financial Officer of Licensee as being true, correct, and complete.


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 6 








 3.8. Currencies. All payments to be paid to Tufts shall be computed and made in
United States Dollars, and Licensee shall use best efforts to convert royalty payments payable on Gross Sales in any country to United States Dollars; provided, however, that if conversion to and transfer of such Dollars cannot be made by Licensee,
its Subsidiaries, or its sublicensees in any country for any reason, Licensee may pay such sums in the currency of the country in which such Gross Sales are made, deposited in Tufts’ name in a bank designated by Tufts in any such country. The
rate of exchange of local currencies to U.S. Dollars shall be at the rate of exchange prevailing at the Bank of Boston (or such other bank in Boston, Massachusetts or New York, New York as Tufts may designate in writing from time to time), for
currencies of the amounts involved, as such rate is stated for the first business day after the end of the period with respect to which the royalties are due. 
 3.9. Records; Audits. Licensee shall keep (and cause to be kept) and maintain complete and accurate records of Gross Sales of the Licensed Products by Licensee, its Subsidiaries, and its
sublicensees, in accordance with generally accepted accounting procedures. Such records shall be accessible to independent certified public accountants selected by Tufts and reasonably acceptable to Licensee, by audits conducted not more than once a
year during the License Period and for one year after the termination thereof, at any reasonable times during business hours, for the purpose of verifying Gross Sales and any royalties due thereon. Such accountants shall disclose to Tufts only
information relating to the accuracy of the records kept and the payments made, and shall be under a duty to keep confidential any other information obtained from such records. Licensee, its Subsidiaries, and its sublicensees shall not be required
to retain such records for more than three (3) years after the close of any calendar quarter-year. No period shall be subject to audit under this Section more than once as to any entity being audited. 

3.10. Substantial Underpayment. If any such audit reveals that the aggregate of royalties paid during any four consecutive
calendar quarters was more than five percent (5%) less than the amount that should have been paid, then the reasonable expenses of the audit shall be borne by Licensee, which shall pay those expenses within thirty (30) days after demand
therefore by Tufts accompanied by the accountants’ statement therefor. 
 ARTICLE IV - TECHNOLOGY DISCLOSURE; PATENT
PROSECUTION. 
 4.1. Demonstration. Within ninety (90) days of the Effective Date, Tufts representative(s)
having knowledge of the Technology and Patent Rights will disclose them to Licensee personnel generally competent in the Field of Use, at the premises of Tufts, or, if mutually agreed, at the premises of Licensee. Such disclosure shall be scheduled
at the mutual convenience of Tufts and Licensee and shall be made in such ways as the parties mutually agree seems most likely to enable those Licensee personnel to learn the Technology and Patent Rights. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 7 








 4.2. Written Disclosure. Tufts may elect to prepare and furnish to Licensee one or
more written descriptions of the Technology and Patent Rights or portions thereof. Licensee agrees to review the written descriptions promptly after receiving them and indicate in writing to Tufts whether there are any details or aspects with which
Licensee does not concur. Absent a sufficiently detailed objection by Licensee, those written descriptions will be deemed binding on the parties for all purposes under this Agreement as to the description of the Technology and Patent Rights so
described. 
 4.3. Availability. Tufts shall perform its obligations under Sections 4.1 and 4.2 for no additional
consideration. Tufts shall not be obligated to devote any particular amount of time to the performance of those obligations as long as Tufts makes its knowledgeable personnel available to competent Licensee personnel as stated above, and devotes the
amount of time reasonably required to teach the necessary Technology to those Licensee personnel. Licensee agrees to make those personnel available for instruction within the time period and otherwise as stated in Section 4.1. 

4.4. Patent Prosecution. Commencing on the Effective Date, Licensee shall have the responsibility to apply for, seek prompt
issuance of, and maintain while the License is in effect, the Patent Rights in the United States, in the foreign countries listed on Exhibit B hereto and in the foreign countries selected by Licensee and Licensee will keep Tufts informed of the
foregoing on a current basis. Upon Tufts’ request, Licensee will file and prosecute patent applications corresponding to the Patent Rights in any one or more other countries, to the extent commercially reasonable. Tufts shall cooperate fully
with Licensee and provide all such information and data and execute any documents reasonably required in order to allow Licensee to conduct such prosecution and Tufts shall have the opportunity to provide substantive review and comment on any such
filing or prosecution. The choice of patent counsel shall be reasonably acceptable to Tufts. 
 4.5. Patent Expenses.
Licensee shall pay all costs associated with the preparation, filing, prosecution, and maintenance of all patent applications filed and patents obtained, which are included in the Patent Rights. 

4.6 Abandonment. In the event that Licensee desires to abandon any patent or patent application within the Patent Rights in any
country, Licensee shall provide Tufts with reasonable prior written notice of such intended abandonment or decline of responsibility, and Tufts shall have the right, at its expense, to prepare, file, prosecute, and maintain the relevant Patent
Rights. If Licensee decides to abandon an issued patent (and all filed applications therefor) throughout the world, or if Licensee determines not to file and prosecute in at least one country a patent application that Tufts has requested Licensee to
file, then in any such event such patent and patent applications shall not thereafter be included in “Patent Rights”, and the non-public information included in (or that would be included in) such
patent and applications shall not thereafter be included in “Technology”. If Licensee decides to abandon an issued patent (or a filed application therefor) in any country, or if Licensee declines to file


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 8 








 
and prosecute a patent application in a country as requested by Tufts herein, then in any such event each such country shall no longer be included in the “Territory” for purposes of the
claims covered by the relevant patent or patent application or for purposes of the non-public information included in (or that would be included in) such patent or application. 

ARTICLE V - CONFIDENTIALITY. 
 5.1. Limitations on Use, Disclosure. Licensee agrees to treat as confidential, and to use and disclose only in furtherance of this Agreement, all Confidential Technology disclosed to it by Tufts.
Licensee agrees that it will exercise every reasonable precaution to prevent the unauthorized disclosure of Confidential Technology by any of its directors, officers, employees, or agents to other parties, other than to Subsidiaries and to Licensee
sublicensees. Any Confidential Technology disclosed to Subsidiaries or sublicensees shall be disclosed on the basis of and subject to the confidentiality provisions of this Agreement. 

5.2. Cessation. Any information which is Confidential Technology at the date of disclosure thereof to Licensee shall cease to be
Technology, and Licensee, its Subsidiaries, and its sublicensees shall be released from the provisions of Section 5.1 as to such information on the date when, through no act or omission on the part of Licensee, its Subsidiaries, or its
sublicensees, such information becomes (a) publicly known by way of a single publication in which such Confidential Technology is disclosed in reasonable detail, (b) so widely known and used in combination that it can be said to be
generally available to the public or (c) is subsequently rightfully obtained without restriction on use or disclosure from sources other than Tufts having no confidential obligation in favor of Tufts. 

5.3. Time Limit. The provisions of this Article V shall continue to apply to any information which is Confidential Technology for
so long as it shall remain such, notwithstanding any termination of this Agreement or the License or expiration of the License Period, provided, however, that the obligations of confidentiality under this Article shall in any event expire and cease
to exist ten years from the Effective Date. 
 ARTICLE VI - DILIGENCE. 

Licensee agrees to use its best efforts to effect introduction of Licensed Products into the United States commercial market as soon as
practical, consistent with sound and reasonable business practices and judgments. Prior to the first commercial sale of a Licensed Product, Licensee shall provide annual reports of such efforts to Tufts within sixty (60) days of each
anniversary of the Effective Date. Tufts shall have the right, at any time after eighteen (18) months from the Effective Date, to terminate the License and Tufts’ obligations under this Agreement if Licensee, within ninety (90) days
after written notice from Tufts of such intended termination, fails to provide written evidence that Licensee has commercialized or is actively attempting to commercialize Licensed Products. Evidence that Licensee has, within eighteen months after
the Effective Date, (i) delivered to Tufts a business plan, (ii) taken all reasonable 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 9 








 
steps to prosecute and maintain the Patent Rights in accordance with the provisions of Section 4.4 hereof, (iii) made payment of all research support under the Sponsored Research
Agreement between the parties of even date herewith and (iv) raised a total of $2 million through venture capital investors or strategic partners shall be deemed, in and of itself, a sufficient showing of such active attempts to commercialize
Licensed Products during such period. Thereafter, evidence that Licensee has achieved the following milestones as scheduled below shall be deemed, in and of itself, a sufficient showing of such active attempts to commercialize Licensed Products
through such date: 
  

	 	(i)	raised a total of $5 million through venture capital investors or strategic partners within three (3) years of the Effective Date; and 


 

	 	(ii)	filed an IND for a Licensed Product in the United States within five (5) years of the Effective Date. 


Tufts shall not unreasonably withhold its assent to any revision of such milestones whenever requested in writing by Licensee and
supported by evidence of technical difficulties or delays that the parties could not have reasonably avoided. 
 Notwithstanding
the foregoing, Tufts shall have the right at any time after ten (10) years from the Effective Date to convert the License hereunder to non-exclusive if Licensee, its Subsidiaries, or its sublicensees have
not by the time of such conversion sold Licensed Products into the United States market. 
 If at any time Licensee decides to
discontinue all programs relating to the MAR operon or all programs relating to tetracycline derivatives, Licensee shall give notice of such intent to Tufts and Tufts shall have the option to terminate the License granted hereunder solely with
respect to such discontinued programs on thirty days notice to Licensee. Upon any such termination, responsibility for the prosecution and maintenance of any Patent Rights on the discontinued programs shall revert to Tufts. 

ARTICLE VII - REPRESENTATIONS, WARRANTIES, AND LIMITATIONS. 

7.1 Tufts Disclaimer. TUFTS MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED (INCLUDING,
WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR PURPOSE), AND ASSUMES NO RESPONSIBILITIES WHATSOEVER, WITH RESPECT TO THE PATENTS OR TECHNOLOGY OR THE USE THEREOF, OR THE MANUFACTURE, POSSESSION, USE, MARKETING, SALE, OR OTHER
DISPOSITION BY TUFTS, LICENSEE, OR ANYONE ELSE, OF LICENSED PRODUCT(S) OR ANY OTHER PRODUCTS OF SERVICES (INCLUDING, WITHOUT LIMITATION, PRODUCTS MADE BY TUFTS, AND TUFTS SERVICES, THAT ARE OR WERE FURNISHED TO LICENSEE AT ANY TIME BEFORE, ON, OR
AFTER THE Effective 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 10 








 
Date), EXCEPT ONLY AS EXPRESSLY STATED BELOW IN THIS ARTICLE VII. Without limitation of the foregoing generality, nothing contained herein or in any disclosure of the Patents or Technology made
by or on behalf of Tufts shall be construed as extending any representation or warranty with respect to the Patents or Technology or Licensed Products or the results to be obtained by the use of the Patents or Technology or any Licensed Products, or
that anything made, used, or sold by use of the Patents or Technology or any part thereof, alone or in combination, will be free from infringement of patents of third parties. TUFTS SHALL NOT BE LIABLE TO LICENSEE, ITS SUBSIDIARIES, ITS
SUBLICENSEES, OR ANY OTHER PARTY, REGARDLESS OF THE FORM OR THEORY OF ACTION (WHETHER CONTRACT, TORT, INCLUDING NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE), FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER EXTRAORDINARY DAMAGES ARISING
OUT OF OR RELATED TO THIS AGREEMENT, PATENTS, THE TECHNOLOGY, THE LICENSED PRODUCTS, OR ANY PRODUCTS OR SERVICES FURNISHED OR NOT FURNISHED BY TUFTS, EVEN IF TUFTS HAS BEEN ADVISED OF THE POSSIBILITY THEREOF. 

Licensee agrees that all warranties, if any, in connection with the sale or other disposition of any Licensed Products (or any products
made by Tufts and furnished at any time to Licensee) by Licensee, its Subsidiaries, or its sublicensees will be made by them and will not directly or impliedly obligate Tufts. 
 7.2 Tufts Representations. Notwithstanding the first sentence of Section 7.1, Tufts: 
 (a) Represents that Tufts is a corporation organized and existing under the laws of the Commonwealth of Massachusetts and has the power and authority to enter into this Agreement. 

(b) Represents that Tufts has taken all necessary action to authorize its execution and delivery of this Agreement by the representatives
of Tufts who carried out such execution and delivery, and to authorize the performance by Tufts of its obligations hereunder. 

(c) Represents that execution and delivery of this Agreement and its performance by Tufts will not result in any breach or violation of,
or constitute a default under, any agreement, instrument, judgment, or order to which Tufts is a party or by which it is bound. 

7.3. Licensee Representations. Licensee represents and warrants to Tufts that: 

(a) Licensee is a corporation organized and existing under the laws of Delaware and has the power and authority to enter into this
Agreement. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 11 








 (b) Licensee has taken all necessary action to authorize its execution and delivery of this
Agreement by the representatives of Licensee who carried out such execution and delivery, and to authorize the performance by Licensee of its obligations hereunder. 
 (c) Execution and delivery of this Agreement and its Agreement and its performance by Licensee will not result in any breach or violation of, or constitute a default under, any agreement, instrument,
judgment, or order to which Licensee is a party or by which it is bound. 
 ARTICLE VIII - INDEMNITY; INSURANCE; INFRINGERS.

 8.1. Indemnity. Licensee agrees to exonerate, indemnify, and hold harmless Tufts, its trustees, officers,
employees, and agents, from all costs, expenses (including attorneys’ fees), interest, losses, obligations, liabilities, and damages paid or liability for which is incurred by any of said parties (“Losses”), and which arise out of or
are in connection with or are for the purpose of avoiding any and all claims, demands, actions, causes of action, suits, appeals, and proceedings (“Claims”), all whether groundless or not, or the settlement thereof, based on any actual or
alleged injuries, damages, or liability of any kind whatsoever (including, without limitation, personal injury, death, property damage, breach of warranty, or breach of contract) arising, directly or indirectly, out of any one or more of: any breach
of Licensee of its representations, warranties, or agreements hereunder; or out of any manufacture, marketing, possession, use, sale, or other disposition of Licensed Products or products furnished by Tufts to Licensee in connection herewith or in
connection with the Research Agreement (whether same occurs during or after the License or during or after the License Period) by Licensee, its Subsidiaries, its sublicensees, or anyone claiming by, through, or under any of them; or any acquisition,
possession, disclosure, or use of the Patents or Technology, or any thereof, by Licensee, its Subsidiaries, its sublicensees, or anyone claiming by, through, or under any of them or the presence of Licensee’s or its Subsidiaries’ or
sublicensee’s officers, agents, employees, invitees or property on Tufts’ premises. 
 8.2. Defense;
Settlement. Licensee shall defend and control negotiation of settlement of any Claim, with counsel of Licensee’s choosing approved in advance by Tufts, which approval shall not be unreasonably withheld. Tufts agrees to cooperate fully in
the defense of any Claim and may participate in the defense with counsel of Tufts’ choosing, such separate counsel to be at Tufts’ expense unless a conflict of interest exists between Licensee and Tufts with respect to the defense, in
which case Tufts’ separate counsel shall be at Licensee’s expense. Any settlement by which Tufts would incur any obligation or liability, whether for the payment of money, the taking of any action, the refraining from any action, or
otherwise, shall require the advance written consent of Tufts, which may be withheld in the sole discretion of Tufts without relieving Licensee of any of its indemnification or other obligations hereunder. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 12 








 8.3. Insurance. Not later than thirty (30) days before the time when Licensee,
any Subsidiary, or any Licensee sublicensee shall, on a commercial basis, make, use, or sell any Licensed Products or any products furnished to Licensee by Tufts at any time (before, on or after the Effective Date) in connection herewith or in
connection with the Research Agreement, and at all times thereafter until the expiration of all applicable statutes of limitation pertaining to any such manufacture, marketing, possession, use, sale or other disposition of any Licensed Products or
the aforesaid products furnished by Tufts (whether same occurs or exists during or after the existence of the License or during or after the License Period), Licensee will at Licensee’s expense, obtain and maintain in full force and effect,
comprehensive general liability insurance, including product liability insurance, protecting Tufts against all claims, suits, obligations, liabilities, and damages, based upon or arising out of actual or alleged bodily injury, personal injury,
death, or any other damage to or loss of persons or property, caused by any such manufacture, marketing, possession, use, sale, or other disposition. Such insurance policy or policies shall be issued by companies rated by A. M. Best as A VIII or
better (or other companies acceptable to Tufts), shall name Tufts as an additional named insured, shall have limits of at least one million dollars ($1,000,000) per occurrence with an aggregate of three million dollars ($3,000,000), shall be non-cancelable except upon thirty (30) days prior written notice to Tufts, and shall provide that as to any loss covered thereby and also by any policies obtained by Tufts itself, Licensee’s policies shall
provide primary coverage for Tufts and Tufts’ policies shall be considered excess coverage for Tufts. 
 8.4.
Certificates: Policies. Licensee will forthwith after the obtaining of such insurance required by Section 8.3, obtain and deliver to Tufts certificates of and copies of, and at all times thereafter deliver without further demand
replacement certificates and copies of, all such insurance policies that are in force and effect. As requested by Tufts but in no event more than once per calendar year, Licensee will furnish to Tufts a complete list, statement, and description of
all insurance called for in this Article, together with certificates and copies of policies for each insurance company issuing any thereof, that such insurance in is full force and effect, that all premiums have been paid, and that such insurance
will not be canceled except upon thirty (30) days prior written notice to Tufts. 
 8.5. Infringers. Each party
shall inform the other promptly in writing of any alleged infringement of the Patent Rights in the Field of Use by a third party, including all details then available. Licensee shall have the right, but shall not be obligated, to prosecute at its
own expense any such infringements, and Tufts agrees that Licensee may join Tufts as a plaintiff at the expense of Licensee. In any infringement action commenced solely by Licensee, all expenses of Licensee shall first be reimbursed and all recovery
for infringement shall be shared [***]% to Tufts and [***]% to Licensee. Licensee shall indemnify Tufts against any order for costs or other payments that may be made against Tufts in such proceedings. 

If Licensee has not taken legal action or been successful in obtaining cessation of the infringement, within one-hundred eighty (180) days of written notification from Tufts of such infringement, or if Licensee elects not to continue prosecuting any legal action against an


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 13 








 
infringer, Tufts shall have the right, but shall not be obligated, to prosecute at its own expense any such infringement. Tufts may join Licensee as a plaintiff in any such infringement suit at
Tufts’ expense. In any such action by Tufts, all expenses of Tufts shall first be reimbursed and all recovery for infringement shall be shared [***]% to Tufts and [***]% to Licensee. 

No settlement, consent judgment or other voluntary final disposition of any suit may be entered into without the consents of Tufts and
Licensee, which consents shall not be unreasonably withheld or delayed. 
 In any infringement suit that either party brings to
enforce the Patent Rights, the other party shall at the request and expense of the party bringing the suit, cooperate in all reasonable respects, including, to the extent possible, obtaining the testimony of its employees and making available
physical evidence in the possession of that party. 
 Licensee shall have the exclusive right in accordance with the provisions
of Section 2.2, to sublicense any alleged infringer in the Territory for the Field of Use, for future use of the Patent Rights. 
 8.6 Declaratory Judgment. If any declaratory judgment action alleging invalidity or non-infringement of any of the Patent Rights shall be brought against
Licensee, Tufts shall have the right at its election made within sixty (60) days after commencement of that action, to intervene and take over the sole defense of the action at its expense. 

ARTICLE IX - LICENSE TERMINATION. 
 9.1. Events. The License granted hereunder may be terminated by Tufts pursuant to Article VI or one of the following subsections: 

(a) Material Default. If Licensee shall fail after thirty (30) days written notice from Tufts to pay to Tufts any royalties
or other payments and payable hereunder, or shall fail in any material way to perform any other agreement required to be performed by Licensee under this Agreement, or if any Subsidiary or sublicensee shall be in material breach of any conditions or
obligations affecting Tufts and compliance with which Licensee is responsible for hereunder, or if any representation or warranty of Licensee contained in this Agreement shall prove to have been inaccurate or misleading in any material way when made
(referred to collectively and individually as a “material default”), then, without limitation of and in addition to any and all other rights and remedies available to Tufts with respect to such material default, Tufts may terminate the
License and Tufts’ obligations hereunder by written notice to Licensee at any time after the expiration of such thirty (30) day notice period if Licensee has not cured the material default and the effects thereof before Tufts gives such
notice of termination to Licensee, unless Licensee commences arbitration proceedings hereunder to contest such material default, in which event Tufts’ right to terminate the License shall be stayed until such arbitration proceedings shall have
been completed. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 14 








 (b) Cessation of Business. If Licensee shall have commenced to carry on the business
of selling any Licensed Products (either directly or through any Subsidiary or sublicensee) and shall at any time thereafter cease for a consecutive period of ninety (90) days to carry on such business actively (either directly or through any
Subsidiary or sublicensee), other than as a result of fire or other casualty or governmental action taken in the absence of Licensee’s fault, Tufts may at any time thereafter while that state of affairs continues, terminate the License by
written notice to Licensee. 
 9.2 Licensee shall have the option at any time to terminate this License upon one-hundred and eighty (180) days’ written notice to Tufts. 
 9.3. Effects.
Upon termination of the License for any reason, nothing herein shall be construed to release Licensee from any obligations hereunder except those of Article VI, but all rights of Licensee and its Subsidiaries and its sublicensees to make, use, or
sell Licensed Products, or to practice the Patents and use the Technology, shall cease immediately, except that Licensee, its Subsidiaries, and its sublicensees may after the effective date of such termination sell all Licensed Products that they
may have on hand at the date of termination, and may complete manufacture of Licensed Products then in the process of manufacture, and sell them, provided that they pay all royalties due thereon with respect to Gross Sales, as provided in this
Agreement. 
 ARTICLE X - NOTICE. 
 Any notice or communication required to be given hereunder in writing shall be given by registered or certified mail, return receipt requested, or delivered by courier, return receipt requested, charges
and postage prepaid, addressed to the parties, respectively, at the following addresses: 
 In the case of Tufts to: 

Joseph J. Byrne, Ph.D. 
 Associate Provost for Research 
 Tufts University 

136 Harrison Avenue 
 Boston, MA 02111 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 15 








 with a copy to: 
 Mason (Skip) Irving, III 
 Vice President, Commercial Development 

Massachusetts Biotechnology Research Institute 
 One Innovation Drive 
 Worcester, MA 01605 

with a second copy to: 
 Mary
Lee Jacobs, Esq. 
 General Counsel 
 Tufts University 
 Ballou Hall 

Medford, MA 02155 
 or in the
case of Licensee to: 
 Walter Gilbert 
 Acting Chief Executive Officer 
 Paratek Pharmaceuticals, Inc. 

P.O. Box 1525 

Boston, MA 02117-1525 
 with a
copy to: 
 Jeffrey M. Wiesen, Esq. 
 Mintz, Levin, Cohn, Ferris, 
   Glovsky & Popeo P.C. 

One Financial Center 
 Boston, MA 02111 
 or at such other respective substitute addresses as the addressee may designate
in writing to the other party. 
 ARTICLE XI - NON-USE OF NAMES. 

Licensee, its subsidiaries and its sublicensees agree that it will not use the name “Tufts University,” or any variant thereof,
or identify Tufts or any portion of Tufts, or any inventor of any of the Patents or Technology, as a party to this Agreement, or as a participant in inventing the inventions of the Patents or creating the Technology, including, without limitation,
in any advertising or promotional sales literature, without the prior express written consent of Tufts, which consent may be withheld or withdrawn by Tufts in its complete and 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 16 








 
uncontrolled discretion for any reason whatsoever and at any time or times. However, notwithstanding the foregoing, Tufts will make no objection to any proper reference by Licensee to published
technical publications by such inventors or creators; and, subject to the confidentiality requirements hereof, Tufts will make no objection to Licensee’s making such disclosures as in the reasonable opinion of legal counsel are required as a
matter of law and such general disclosures of this Agreement as may be desired by Licensee for purposes of grant solicitations from governmental authorities or as reasonably necessary (as reasonably determined by Licensee) for the purposes of
obtaining financing for Licensee or as reasonably necessary (as reasonably determined by Licensee) for the conduct of its business, other than advertising or sales promotion. Licensee shall impose and enforce the requirements of this Article on its
Subsidiaries and sublicensees. 
 ARTICLE XII - COMPLIANCE WITH LAWS. 

12.1. Export Controls. The Export Control Regulations of the U. S. Department of Commerce prohibit, except under special
validated license, the exportation from the United States of technical data relating to certain commodities (listed in the Regulations), unless the exporter has received certain written assurance from the foreign importer. In order to facilitate the
exchange of technical information under this Agreement, Licensee therefore hereby agrees and gives its assurance to Tufts that Licensee will not, unless any required prior authorization is obtained from the U. S. Office of Export Control, re-export directly or indirectly any technical data received from Tufts under this Agreement and will not export directly the Licensed Products or such technical data to any country listed on either the Commodity
Control List or Militarily-Critical Technologies List. Tufts makes no representation as to whether any such license is required or, if one is required, as to whether it will be issued by the U. S. Department of Commerce. 

12.2. Other Laws. In addition to the foregoing export control requirements, Licensee agrees that it, its Subsidiaries, and its
sublicensees will comply with all applicable mandatory or permissive patent marking laws, rules, and regulations and comply with all other laws, rules, and regulations of all governmental authorities applicable to any of their activities
contemplated by this Agreement, and will comply with all necessary and desirable practices in connection and compliance with safety recommendations of trade associations or governmental authorities. 

ARTICLE XIII - MISCELLANEOUS PROVISIONS. 
 13.1. Assignment. Licensee shall not assign the License or this Agreement without the prior written consent of Tufts, which consent shall not be unreasonably withheld; provided, however, that
Licensee, without such consent, may assign all of its rights hereunder to a wholly-owned Subsidiary or to the acquiring party in connection with the transfer of all or substantially all of its business and assets to an acquiring party or in the
event of its merger or consolidation with that acquiring party, if and only if the assignee shall assume all obligations 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 17 








 
of Licensee under this Agreement. However, no assignment or other transfer by Licensee shall relieve Licensee of any obligations hereunder and Licensee shall continue to be primarily and jointly
and severally liable (along with such assignee or other transferee) for the performance of all obligations of Licensee and such assignee or other transferee hereunder. 
 13.2. Independent Contractors. The parties hereto shall be independent contractors with respect to each other, and nothing contained herein shall be construed as constituting either of them as the
agent, principal, employee, servant, joint venturer, or partner of the other for any purpose whatsoever. 
 13.3 Governing
Law. This Agreement shall be governed by and construed in accordance with Massachusetts law, without regard to its conflict of laws principles. 
 13.4. Sole Agreement. This Agreement and any Exhibits annexed hereto (each of which is hereby made part hereof by this reference), and any other documents which may be expressly incorporated by
reference herein, constitute the entire and only agreement between the parties concerning the subject matter hereof; and all prior negotiations, representations, warranties, agreements, and understandings related thereto are superseded hereby.

 13.5. Severability. If any provision of this Agreement shall to any extent be found to be invalid
or unenforceable, the remainder of this Agreement shall-not be affected thereby, and any such invalid or unenforceable provision shall be reformed so as to be valid and enforceable to the fullest extent permitted by law. 

13.6. Headings. Headings of Articles, Sections, and subsections included herein are for convenience of reference only and shall
not be used to construe this Agreement. 
 13.7. Financial Confidentiality. Both parties agree to keep the financial
terms of this Agreement confidential. 
 ARTICLE XIV - ARBITRATION. 

14.1. Arbitration. Subject to Section 14.2 below, all disputes, controversies, or differences which may arise between the
parties out of or in relation to or in connection with this Agreement, or for the breach thereof, which cannot be resolved by mutual agreement, shall be finally settled by arbitration to be held in accordance with the Commercial Arbitration Rules
(the “Rules”) of the American Arbitration Association (the “Association”) as the Rules then exist, in Boston, Massachusetts, with the following deviations from the Rules. The arbitrators shall consist of one Tufts nominee, one
Licensee nominee, and a third person jointly selected by those two nominees. The party requesting arbitration shall designate its nominee in the request, which shall be addressed to the Association with a simultaneous copy to the other party. If the
other party shall fail within thirty (30) days of the request for arbitration to nominate the second arbitrator or if the two arbitrators are unable to agree upon the third 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 18 








 
arbitrator within thirty (30) days after selection of the second arbitrator, then in either case the arbitration panel will be completed according to the Rules. Both legal and equitable
remedies shall be available to the arbitrators. The award of a majority of the arbitration panel shall be final and binding on the parties hereto and shall be enforceable in any court having jurisdiction. Tufts and Licensee each irrevocably consent
and submit to the jurisdiction of the courts of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. 
 14.2. Judicial Relief. Claims, disputes, or controversies concerning the validity, infringement, construction, or effect of any patent including, without limitation, any patent licensed hereunder,
shall be resolved in any court having jurisdiction thereof, and the parties submit to the jurisdiction of the United States District Court for the District of Massachusetts. In the event that, in any arbitration proceeding, any issue shall arise
concerning the validity, infringement, construction, or effect of any patent licensed hereunder, the arbitrators shall assume the validity of all claims as set forth in such patent. In any case, the arbitrators shall not delay the arbitration
proceeding for the purpose of obtaining or permitting either party to obtain judicial resolution of such an issue, unless an order staying such arbitration proceeding shall be entered by a court of competent jurisdiction. Neither party shall raise
any issue concerning the validity, infringement, construction, or effect of any patent licensed hereunder in any proceeding to enforce any arbitration award hereunder in any proceeding otherwise arising out of any such arbitration award. Nothing in
Section 14.1 shall be construed to waive any rights or timely performance of any obligations existing under this Agreement. Moreover, each party acknowledges that appropriate cases (as determined by the courts of competent jurisdiction) of a
violation by either party of any of the provisions of this Agreement may entitle the other party to equitable judicial relief, and this relief shall be available in addition to, and shall not be unavailable by reason of, the arbitration provisions
of Section 14.1, above. Such equitable judicial relief may be by temporary restraining orders, preliminary and permanent injunctions, and such other equitable relief as any court of competent jurisdiction may deem just and proper. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 19 








 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this License
Agreement to be effective as of the Effective Date. 
  

											
	TUFTS UNIVERSITY	 		 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Steven S. Manos
	 		 	By:	 	 /s/ Walter Gilbert

		 	Signature	 		 		 	Signature
					
	 Steven S. Manos
	 		 		 		 	  

						
		 	Typed Name	 		 		 		 	Typed Name
					
	 Executive Vice President
	 		 		 		 	  

						
		 	Title	 		 		 		 	    Title
					
	     3/19/97
	 		 		 		 	     4/23/97

						
		 	Date	 		 		 		 	    Date


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 20 








 EXHIBIT A 
 TO 
 LICENSE AGREEMENT 

BETWEEN 
 TUFTS
UNIVERSITY AND PARATEK PHARMACEUTICALS, INC. 
 Existing Patent Rights (Including Existing Applications) 

 

	 	I.	Issued Patents:            (See attached Patent Summary) 


“Patent Rights” shall also include the patents to be applied for pursuant to the terms of the License Agreement after the Effective Date, after
such applications are made. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 21 








 Patent Summary 
 Stuart B. Levy, Ph.D. 
 January 1997 

 

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 22 








 EXHIBIT B 

List of Foreign Countries in which Patents are to be Filed. 
 United States 
 Canada 

Japan 

  Europe (Germany, Belgium, France, Italy, Spain and United Kingdom) 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 22 








 TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. 

AMENDMENT NO. 1 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A is hereby amended to include: 
  

	•	 	 Provisional patent application “[***]”, Filed [***] 



 

	•	 	 Patent application “[***]”, Filed [***] 


 Section 1.4. “Field of Use” is hereby replaced by the following: 
 1.4. “Medical Field of Use” shall mean the prophylaxis, treatment or prevention of bacterial or microbial diseases or medical conditions in humans or animals or agriculture through the direct
administration of (i) tetracycline derivatives or other compounds which affect tetracycline resistance or (ii) compounds based on knowledge of the MAR operon or (iii) compounds involving novel genes which affect antibiotic resistance
or microbial infectivity and which are derived from studies of the MAR operon or (iv) compounds that affect any such genes. 
 “Disinfectant Field of Use” shall mean the use of compositions, including but not limited to disinfectants and soaps, in any manner other than the direct administration to humans or animals or
agriculture, to kill or reduce the growth rate of microorganisms, where such compositions include (i) tetracycline derivatives or other compounds which affect tetracycline resistance or (ii) compounds based on knowledge of the MAR operon
or (iii) compounds involving novel genes which affect antibiotic resistance or microbial infectivity and which are derived from studies of the MAR operon or (iv) compounds that affect any such genes. 

“Field of Use” shall mean the Medical Field of Use and Disinfectant Field of Use, collectively. 

Section 1.7. Third paragraph is hereby amended to read: “In the event that a Licensed Product in the Medical Field of Use under this
Agreement is sold...” 
 Section 3.4 Running Royalties is hereby replaced by the following: 

3.4. Running Royalties. 
 For the Medical Field of Use, Licensee agrees to pay to Tufts royalties of: 
 (a)
[***] percent ([***]%) of the Gross Sales of Licensed Products, the making, using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and non-lapsed patent
included in the Patent Rights; or 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 1 








 (b) [***] percent ([***] %) of the Gross Sales of Licensed Products that do not fall within
the clause (a), above, but the manufacture, use or sale of which would infringe (were it not for the License) at least one claim in a pending application included in the Patent Rights, if such claim were to issue. 

For the Disinfectant Field of Use, Licensee agrees to pay to Tufts royalties of: 

[***] percent ([***]%) of the Gross Sales of Licensed Products, the making, using, or selling of which infringes (were it not for the
License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights or would infringe (were it not for the License) at least one claim in a pending application included in
the Patent Rights, if such claim were to issue. 
 Section 3.5. Sublicense Royalties is hereby replaced by the following:

 3.5. Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts [***] percent
([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for
research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. 

For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent
([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a
Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold
the Licensed Product. 
 For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts
the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included
in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee,
rather than the sublicensee, had sold the Licensed Product. 
 All other provisions of the Agreement remain unchanged and in full force and
effect. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 2 









											
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
						
	By:	 	 /s/ Philip G. Salem
	 		 		 	By:	 	 /s/ George C. Hillman

		 	    (signature)	 		 		 		 	    (signature)
				
	 Philip G. Salem
	 		 		 	 George C. Hillman

				
	Name	 		 		 	Name
				
	 Senior Director, University Development
	 		 		 	 Executive Vice President

				
	Title	 		 		 	Title
				
	 12/23/97
	 		 		 	 12/29/97

				
	 Date
	 		 		 	 Date



  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. 

AMENDMENT NO. 2 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A is hereby amended to include: 
  

	•	 	 Patent application entitled: “[***]” Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***].



  

	•	 	 Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] 



 

	•	 	 Patent application jointly owned with [***], entitled: “[***]”, Serial No.: [***], Filed [***] 



 

	•	 	 Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] 



 

	•	 	 Patent application entitled: “[***]”, Serial No.: [***], Filed [***] 



 

	•	 	 Patent application entitled: “[***]”, U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***]



 All other provisions of the Agreement remain unchanged and in full force and effect. 

 

											
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
						
	By:	 	 /s/ Margaret Newell
	 		 		 	By:	 	 /s/ George C. Hillman

						
		 	(signature)	 		 		 		 	(signature)
				
	 Margaret Newell
	 		 		 	 George C. Hillman

				
	Name	 		 		 	Name
				
	 Executive Vice President and Associate Provost for Research
	 		 		 	 Chief Operating Officer

				
	Title	 		 		 	Title
				
	       7/31/98
	 		 		 	       7/31/98

				
	Date	 		 		 	Date


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 3 
 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and
modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License
Agreement dated February 1, 1997. 
 All other provisions of the Agreement as amended remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below.

  

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

		 	Margaret Newell, Associate Provost for Research	 		 		 	George Hillman, Executive Vice President
					
	Date:	 	 6/3/99
	 		 	Date:	 	 6/3/99



  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
 Compositions and Methods Related to Antibiotic
Resistance 
  

			
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 1 – 









 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 Compositions and Methods Related to Antibiotic Resistance 

 

			
	 [***]
	  	[***]
	 [***]
	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 2 – 









 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 TETRACYLINE 

 

			
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 3 – 









 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 COMPOSITIONS AND METHODS RELATED TO ANTIBIOTIC RESISTANCE 

DISCLOSURES 
  

			
	 [***]
	  	[***]
	 [***]
	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 4 – 









 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 TETRACYCLINE DISCLOSURES 

 

			
	 [***]
	  	
	 [***]
	  	[***]
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 5 – 









 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 TETRACYCLINE DISCLOSURES (continued) 

 

			
	 [***]
	 	
	 [***]
	 	
	 [***]
	 	


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 6 – 








 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 4 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and
disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such
action replace all prior versions of Exhibit A. 
 All other provisions of the Agreement as amended remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below.

  

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

	Margaret Newell, Associate Provost for Research	 		 		 	George Hillman, Executive Vice President
					
	Date:	 	 8/9/00
	 		 	Date:	 	 8/14/00



  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









					
	Updated August 8, 2000	  	Exhibit A	  	
		  	  
 CONFIDENTIAL

ATTORNEY-CLIENT PRIVILEGED
  

PARATEK PHARMACEUTICALS, INC.
 PATENT STATUS SHEET
	  	

  

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or

Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 1 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 2 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 3 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 4 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 5 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 6 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 7 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 8 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 9 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  		  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  		  		  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 10 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 


											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  		  		  	
	 [***]
	  		  	[***]	  		  		  	[***]
	 [***]
	  		  	[***]	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 11 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET (FOREIGN)

  


											
	 Docket No.
	  	 Region/

Country
	  	 Appln. No./

Patent No.
	  	 Title and Description
	  	 Appln. Date/

Grant date
	  	 Status

	(Firm of Record)	  	 	  	 	  	 	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 12 – 









 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET (FOREIGN)

  


											
	 Docket No.
	  	 Region/

Country
	  	 Appln. No./

Patent No.
	  	 Title and Description
	  	 Appln. Date/

Grant date
	  	 Status

	(Firm of Record)	  	 	  	 	  	 	  	 	  	 
						
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 13 – 








 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 5 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and
disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such
action replace all prior versions of Exhibit A. 
 All other provisions of the Agreement as amended remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below.

  

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

	Margaret Newell	 		 	George Hillman
	Associate Provost for Research	 		 	Executive Vice President
					
	Date:	 	 9/10/01
	 		 	Date:	 	 9/10/01



  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 EXHIBIT A 

CONFIDENTIAL 
 PATENT SUMMARY 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 1 – 









													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 2 – 









													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 3 – 









													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 4 – 








 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 6 
 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and
modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License
Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such action replace all prior versions of Exhibit A. 

All other provisions of the Agreement as amended remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below. 

 

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

		 		 		 		 	George Hillman
		 		 		 		 	Executive Vice President
					
	Date:	 	 12/11/02
	 		 	Date:	 	 12/11/02



  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 1 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  		  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  		  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 2 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 3 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 4 








 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 1 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  		  		  	[***]
	[***]	  	[***]	  	[***]	  		  		  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 2 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 3 








 TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. 

AMENDMENT NO. 7 
 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Section 3.4 Running Royalties is hereby
replaced by the following: 
 3.4 Running Royalties. 
 For the Medical Field of Use, Licensee agrees to pay to Tufts royalties of: 
 (a)
[***] percent ([***]%) of the Gross Sales of Licensed Products, the making using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and non-lapsed patent
included in the Patent Rights; or 
 (b) [***]percent ([***]%) of the Gross Sales of Licensed Products that do not fall within
clause (a), above, but the manufacture, use, or sale of which would infringe (were it not for the License) at least one claim in a pending patent application included in the Patent Rights, if such claim were to issue. 

For the Disinfectant Field of Use, Licensee agrees to pay to Tufts royalties of: 

[***] percent ([***]%) of the Gross Sales of Licensed Products, the making using, or selling of which infringes (were it not for the
License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights or would infringe (were it not for the License) at least one claim in a pending patent application
included in the Patent Rights, if such claim were to issue. 
 Section 3.5 Sublicense Royalties is hereby replaced by the following:

 3.5 Sublicense Fees and Royalties. 
 For the Medical Field of Use, Licensee agrees to make the following payments to Tufts: 
 (a) Sublicense Fees. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts [***] percent ([***]%) of that portion of any sublicense issue fees or
license maintenance fees received by Licensee that are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product
development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. 

(b) Sublicense Royalties. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the
lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending
application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the
sublicensee, had sold the Licensed Product. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 For the Disinfectant Field of Use, Licensee agrees to make the following payments to Tufts: 

(c) Sublicense Fees. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts
[***]percent ([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee that are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a
sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. 

(d) Sublicense Royalties. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts
the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a
pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather
than the sublicensee, had sold the Licensed Product. 
 ARTICLE VI — DILIGENCE clause (ii) of the fifth sentence is hereby
amended to read: 
 (ii) filed an IND for a Licensed Product in the United States within seven (7) years of the Effective
Date. 
 ARTICLE VI — DILIGENCE Third paragraph is hereby amended to read: “Notwithstanding the forgoing, Tufts shall have the
right at any time after twelve (12) years from the Effective Date to convert the License...” 
 Exhibit A and all amendments
and modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License
Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such action replace all prior versions of Exhibit A. 

All other provisions of the Agreement as amended remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below. 

 

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ Thomas J. Bigger

	Margaret Newell	 		 	Thomas J. Bigger
	Associate Provost for Research	 		 	President and Chief Executive Officer
					
	Date:	 	 7/1/03
	 		 	Date:	 	 6/17/03



  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  		  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  		  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 









 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  


													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]


  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 








 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 AMENDMENT NO. 8 TO THE 
 TUFTS UNIVERSITY LICENSE AGREEMENT

 This Amendment No. 8 to the Tufts University License Agreement (this “Amendment”), dated as of
November 20, 2012 (the “Amendment Effective Date”) is by and between Paratek Pharmaceuticals, Inc. (“Licensee”), and Tufts University, a/k/a Trustees of Tufts College (“Tufts”). Each of
Licensee and Tufts is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. 
 WHEREAS, the Parties entered into the Tufts University License Agreement, effective as of February 1, 1997 and entered into amendments thereto: Amendment No. 1 dated as of December 29,
1997, Amendment No. 2 dated July 31, 1998, Amendment No. 3 dated June 3, 1999, Amendment No. 4 dated August 14, 2000, Amendment No. 5 dated September 10, 2001, Amendment No. 6 dated December 11,
2002, Amendment No. 7 dated July 1, 2003 and the letter agreement dated September 17, 2009 (the “Novartis Amendment”), as so amended, the “License Agreement”; and 

WHEREAS, the Parties now wish to further amend the License Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	 	1.	Amendments to Agreement. 


(a) The definition of Field of Use in Section 1.4 of the License Agreement is hereby deleted in its entirety and the following is
hereby inserted in lieu thereof: 
 “Medical Field of Use” shall mean the prophylaxis, treatment or
prevention of all diseases or medical conditions in humans, animals and/or agriculture, including bacterial or microbial diseases, through the direct administration of (a) tetracycline derivatives or (b) compounds which affect tetracycline
resistance or (c) compounds based on knowledge of the MAR operon or (d) compounds involving novel genes which affect antibiotic resistance or microbial infectivity and which are derived from studies of the MAR operon or (e) compounds
that affect any such genes. 
 “Disinfectant Field of Use” shall mean the use of compositions,
including but not limited to disinfectants and soaps, in any manner other than the direct administration to humans or animals or agriculture, to kill or reduce the growth rate of microorganisms, where such compositions include (a) tetracycline
derivatives or (b) compounds which affect tetracycline resistance or (c) compounds based on knowledge of the MAR operon or (d) compounds involving novel genes which affect antibiotic resistance or microbial infectivity and which are
derived from studies of the MAR operon or (e) compounds that affect any such genes. 







 “Field of Use” shall mean the Medical Field of Use and
Disinfectant Field of Use, collectively. 
 (b) The definition of Licensed Products in Section 1.6 of the License
Agreement is hereby amended by adding the following at the end of the definition: 
 “For purposes of clarity, the Parties
hereby agree that [ * ] shall be treated as Licensed Products.” 
 (c) The first sentence of Section 3.3 of the
License Agreement is hereby deleted in its entirety and the following is hereby inserted in lieu thereof: 

“Licensee agrees to pay to Tufts a minimum royalty payment of Twenty Five Thousand Dollars ($25,000) at the end of
each twelve-month period commencing on each anniversary of the Effective Date.” 
 (d) Section 3.4 of the License
Agreement is hereby deleted in its entirety and the following is hereby inserted in lieu thereof: 
 “3.4
Running Royalties. 
 For the Medical Field of Use, Licensee agrees to pay to Tufts royalties of: 

[ * ] percent ([ * ]%) of the Gross Sales of Licensed Products, (a) that are comprised of or contain
Licensed Compounds or (b) the making, using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights or would infringe (were it not for the
License) at least one claim in a pending patent application included in the Patent Rights, if such claim were to issue. 
 For
the Disinfectant Field of Use, Licensee agrees to pay to Tufts royalties of: 
 [ * ] percent ([ *
]%) of the Gross Sales of Licensed Products, (a) that are comprised of or contain Licensed Compounds or (b) the making, using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and
non-lapsed patent included in the Patent Rights or would infringe (were it not for the License) at least one claim in a pending patent application included in the Patent Rights, if such claim were to issue.” 

(e) The following new Section 3.6A of the License Agreement is hereby inserted immediately before Section 3.6: 

“3.6A Licensee Challenge. In the event Licensee, its affiliates or subsidiaries, directly or indirectly through a third party,
initiates a Challenge or assists any party in doing so then, commencing on the date that such Challenge is initiated and continuing until such Challenge is irrevocably withdrawn: (a) the [ * ] shall be [ * ] and
(b) Licensee’s right to withhold any royalty identified in Section 3.6 shall not be applicable, in the case of each of (a), (b) and (c) of Section 3.6 until such Challenge has been withdrawn irrevocably. As used herein,
the term “Challenge” shall mean any challenge to the validity or enforceability of any patents or patent applications owned in whole or in part by Tufts by: (a) filing a declaratory judgment action in which any such patents or patent
applications is alleged to be invalid or unenforceable; (b) filing a request for re-examination of 

  
 2 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 
any of such patents or patent applications pursuant to 35 U.S.C. §302 and/or §311, or provoking or becoming party to an interference with an application for any such patents or patent
applications pursuant to 35 U.S.C. §135; or (c) filing or commencing any post grant review, inter partes review, third party observation, derivation, opposition, cancellation, nullity or similar proceedings against any of such patents or
patent applications.”  
 (f) The fourth paragraph of Article VI of the License Agreement is hereby deleted in its
entirety and the following is hereby inserted in lieu thereof: 
 “Notwithstanding the foregoing, Tufts shall have the
right at any time after [ * ] to convert the License hereunder to non-exclusive if Licensee, its Subsidiaries or its sublicensees have not by the time of such conversion met each of the following milestones by the applicable date: 

 

			
	 Milestone
	 	 Due By

	[ * ]	 	

 (g) The Novartis Amendment is hereby terminated and of no further force and effect. 

2. Payment of Minimum Royalty Fee. The $25,000 Minimum Royalty Fee for the license period through the Amendment Effective Date
shall be paid by Licensee to Tufts within [ * ] days of the date that Licensee receives an invoice from Tufts on and after the Amendment Effective Date. 
 3. Further Clarification of Terms. Tufts hereby agrees to cooperate with Licensee, including by taking such actions reasonably requested by Licensee, to enforce, commercialize products under,
protect and/or maintain foreign patents or patent applications included as Patent Rights under the License Agreement, as amended by the Amendment, in each case including any divisions, continuations, continuations-in-part, re-examinations,
extensions, renewals, or reissues of such patents or patent applications. Licensee hereby agrees to cooperate with Tufts to properly reflect the rights of Tufts in any patents or patent applications covering any products that include or contain any
compound identified as a lead by Paratek, in each case including any divisions, continuations, continuations-in-part, re-examinations, extensions, renewals, or reissues of such patents or patent applications. Licensee will file and prosecute patent
applications or claims to pending patent applications corresponding to the Patent Rights as reasonably requested by Tufts. Licensee shall reimburse Tufts for its reasonable attorneys’ fees and out-of-pocket costs incurred on and after the
Amendment Effective Date in so doing, up to a maximum amount equal to $[ * ] for the period commencing on the Amendment Effective Date and ending on January 31, 2014 and $[ * ] each twelve (12) month period thereafter, which
shall be payable in arrears within [ * ] days upon submission by Tufts to Licensee of an invoice evidencing such fees and costs.  
 4. Covenant. The Parties hereby covenant and agree to use commercially reasonable efforts to reach a mutually satisfactory agreement on an amendment to Exhibit A to the License Agreement as
soon as practicable after the Amendment Effective Date and before [ * ]. 

  
 3 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 5. Confirmation. Tufts hereby confirms to Licensee that Licensee, as of the date of
the Amendment: (a) has provided to Tufts all annual and any other reports required pursuant to Article VI of the License Agreement; and (b) has made the payments required by Sections 3.1, and 3.3 (including but not limited to Sponsored
Research Agreement payments) under the License Agreement. 
 6. Miscellaneous. The Parties hereby confirm and agree that
the License Agreement, as amended hereby and as further provided in this Amendment, together shall constitute the entire amended License Agreement among the parties, remains in full force and effect and is a binding obligation of the Parties hereto.
This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [Remainder of page intentionally left blank.] 

  
 4 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the Amendment
Effective Date. 
  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	/s/ Dennis Molnar
	 Name:
 Title:
	 	 Dennis Molnar
 President and
Chief Executive Officer



  

			
	 TUFTS UNIVERSITY A/K/A TRUSTEES OF
 TUFTS COLLEGE

		
	By:	 	/s/ David R. Harris
	 Name:
 Title:
	 	 David R. Harris

Provost & Senior Vice President




  
 5 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 AMENDMENT NO. 9 TO THE 
 TUFTS UNIVERSITY LICENSE AGREEMENT

 This Amendment No. 9 to the Tufts University License Agreement (this “Amendment”), dated as
of June 24th, 2014 (the “Amendment Effective Date”) is by and between Paratek Pharmaceuticals, Inc. (“Licensee”), and Tufts University, a/k/a Trustees of Tufts College (“Tufts”). Each of
Licensee and Tufts is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. 
 WHEREAS, the Parties entered into the Tufts University License Agreement, effective as of February 1, 1997 and entered into amendments thereto: Amendment No. 1 dated as of
December 29, 1997, Amendment No. 2 dated July 31, 1998, Amendment No. 3 dated June 3, 1999, Amendment No. 4 dated August 14, 2000, Amendment No. 5 dated September 10, 2001, Amendment No. 6 dated
December 11, 2002, Amendment No. 7 dated July 1, 2003 and Amendment No. 8 dated November 20, 2012, as so amended, the “License Agreement”; and 

WHEREAS, the Parties now wish to further amend the License Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	 	1.	Amendments to Agreement. 


(a) The fourth paragraph of Article VI of the License Agreement is hereby deleted in its entirety and the following is hereby inserted
in lieu thereof: 
 “Notwithstanding the foregoing, Tufts shall have the right at any time after [ * ] to convert the
License hereunder to non-exclusive if Licensee, its Subsidiaries or its sublicensees have not by the time of such conversion met each of the following milestones by the applicable date: 

 

			
	 Milestone
	 	 Due By

	[ * ]	 	

 (b) The Covenant in Section 4 of Amendment No. 8 is hereby deleted in its entirety and the
following is hereby inserted in lieu thereof: 
 “4. Covenant. The Parties hereby covenant and agree to use
commercially reasonable efforts to reach a mutually satisfactory agreement on an amendment to Exhibit A to the License Agreement as soon as practicable after the Amendment Effective Date and before [ * ].” 







 2. Payment of outstanding Minimum Royalty Fees due under Section 2 of Amendment
No. 8. The $25,000 Minimum Royalty Fee described in the invoice dated [ * ] and attached as Appendix A to this Amendment No. 9 shall be paid by Licensee to Tufts by [ * ]. The $25,000 Minimum Royalty Fee described in the
invoice dated [ * ] and attached as Appendix B to this Amendment No. 9 shall be paid by Licensee to Tufts within by [ * ]. 
 3. Miscellaneous. The Parties hereby confirm and agree that the License Agreement, as amended hereby and as further provided in this Amendment, together shall constitute the entire amended License
Agreement among the parties, remains in full force and effect and is a binding obligation of the Parties hereto. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. 
 [Remainder of page intentionally left blank.] 

  
 2 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the Amendment
Effective Date. 
  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	/s/ Dennis Molnar
	 Name:
 Title:
	 	 Dennis Molnar
 President and
Chief Executive Officer



  

			
	 TUFTS UNIVERSITY A/K/A TRUSTEES OF
 TUFTS COLLEGE

		
	By:	 	/s/ Diane L. Souvaine
	 Name:
 Title:
	 	 Diane L. Souvaine

Vice-Provost for Research




  
 3 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 Appendix A 
 TUFTS UNIVERSITY 
 Office for Technology Licensing and Industry Collaboration

 136 Harrison Avenue, Suite 75K-950 
 Boston, MA 02111 
 FEIN 04 210 3634 

[ * ]  
 Tufts invoice
13/OTLIC/083 (revised) 
 By email to dmolnar@Paratekpharm.com 
 Dennis Molnar 
 President, Chief Executive Officer 

Paratek Pharmaceuticals, Inc. 
 75 Kneeland
Street 
 Boston, MA 02111 
  

	Re:	Tufts University—Paratek Pharmaceuticals License Agreement 

 effective February 1, 1997 
 Amendment 8 of November 20, 2012 

Amendment to section 3.3 
 Minimum royalty payment of twenty five thousand dollars at the end of each twelve month period commencing on each anniversary of effective date 
 INVOICE 
 Fee due for license period through the amendment 8 effective date 

February 1, 2012, through January 31,
2013                                         
                       $25,000.00 
 Please make your check payable to Tufts University and send it to 
 Thomas McVarish 

Tufts University 
 Office of the Vice Provost

 Suite 75K-950 
 136 Harrison Avenue

 Boston, MA 02111 
 Phone
• [ * ] E-mail • [ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 








 Appendix B 
 TUFTS UNIVERSITY 
 Office for Technology Licensing and Industry Collaboration

 136 Harrison Avenue, Suite 75K-950 
 Boston, MA 02111 
 FEIN 04 210 3634 

[ * ]  
 Tufts invoice
14/OTLIC/062 
 By email to dmolnar@Paratekpharm.com 
 Dennis Molnar 
 President, Chief Executive Officer 

Paratek Pharmaceuticals, Inc. 
 75 Kneeland
Street 
 Boston, MA 02111 
  

	Re:	Tufts University—Paratek Pharmaceuticals License Agreement 

 effective February 1, 1997 
 Amendment 8 of November 20, 2012 

Amendment to section 3.3 
 Minimum royalty payment of twenty five thousand dollars at the end of each twelve month period commencing on each anniversary of effective date 
 INVOICE 
 Fee due for license period 
 February 1, 2013, through January 31,
2014                                         
                   $25,000.00 
 Please make your
check payable to Tufts University and send it to 
 Thomas McVarish 
 Tufts University 
 Office of the Vice Provost 

Suite 75K-950 
 136 Harrison Avenue 

Boston, MA 02111 
 Phone • [ * ]
E-mail • [ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.